Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Surviving a Scandal: How to Expect the Unexpected

$5,000.00

The Institute of Crisis Management defines a crisis as “any problem or disruption that triggers negative stakeholder reaction and that could impact the organization’s financial strength and ability to do what it does.” In the pharmaceutical setting, a crisis could mean an adverse clinical trial event, the bankruptcy of an essential service provider, or a serious product recall. It could be an event that is within the company’s control and has been mishandled, or an external situation that forces the business to change its strategic course, either temporarily or permanently.
November 3, 2016
Find out more
Betrixaban
Read More
Betrixaban (Portola Pharmaceuticals) is an oral, once-daily inhibitor of factor Xa that catalyzes conversion of prothrombin to thrombin, preventing thrombosis. Betrixaban is currently in Phase III development…
August 2, 2016
Find out more
Kengreal
Read More
Kengreal (cangrelor; AstraZeneca) targets a previously unmet need in the acute treatment of

myocardial infarction (MI) patients receiving percutaneous coronary intervention (PCI) on account of

its intravenous formulation and quick onset of action.
April 14, 2016
Find out more
Alunbrig
Read More
Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
September 8, 2018
Find out more
European Surgical Procedure Volumes: Breast, general, gynecologic, organ transplant, neurosurgical, ophthalmalogic, and urologic

$3,000.00

This report presents procedure volumes forecasts for some of the most common surgical procedures performed in the five EU countries of France, Germany, Italy, Spain, and the UK (5EU).
December 12, 2017
Find out more
Bavencio
Read More
Bavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein.
March 6, 2019
Find out more
Key Trends in European Market Access

$2,995.00

This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.
January 26, 2016
Find out more
Sovaldi
Read More
Sovaldi (sofosbuvir; Gilead) was the first interferon-free regimen to be approved for genotype 2/3 (GT-

2/3) patients, and has greatly benefited from the lucrative warehoused population and lack of

competitors in this subgroup.
November 6, 2017
Find out more
Disease Analysis: Melanoma
Read More
Melanoma accounts for just 1% of all skin cancer cases, but is responsible for the majority of skin cancer-related deaths. Melanoma occurs when melanocytes – pigment-producing cells of the skin that are intercalated in the basal cell layer – become malignant. Although surgical excision is a potentially curative option for many melanoma patients, the disease can disseminate rapidly. Currently, only 27.3% of patients diagnosed with distant metastatic melanoma survive for five years, compared to about 99.0% of those with localized disease. Although 83% of patients present with localized disease, approximately one quarter to one third of these patients will eventually experience disease recurrence.
June 22, 2022
Find out more
Disease Analysis: Migraine
Read More
Migraine is a common, disabling, and recurring neurological disorder characterized by severe headache co-occurring with nausea, vomiting, and other symptoms, the duration of which can range from hours to days.
June 16, 2022
Find out more
U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management

$4,750.00

More than 40% of people in the U.S. say they have experienced recent pain, with 8% suffering from chronic pain. Direct healthcare costs associated with the treatment of pain total nearly $300 billion annually.
April 4, 2016
Find out more
Corlanor
Read More
Corlanor (ivabradine; Servier/Amgen/Ono Pharmaceutical) blocks f-channels and inhibits the f-current, a modulator of the heart’s pacemaker activity.
December 11, 2017
Find out more
Schizophrenia and Bipolar Disorder KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.
April 28, 2021
Find out more
Atopic Dermatitis and Psoriasis KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.
November 18, 2021
Find out more
United Kingdom, Surgical Procedure Volumes

$4,850.00

This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union member state of the U.K.
September 22, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *